“The Tesla and SpaceX CEO sent an email to employees at both companies on Tuesday saying everyone must spend 40 hours per week in the office. ‘If you don’t show up, we will assume you have resigned. The more senior…
HOME > ACADEMIA
ACADEMIA
- Japan Diabetes Society Crosses Out SMART Study from Its Guidelines
February 25, 2014
- US Journal Officially Announces Retraction of SMART Study
February 24, 2014
- Japan Hypertension Society Halts Support for Maker-Linked Seminars, but Gives Leeway for Luncheons
February 18, 2014
- University of Tokyo Hospital Allegedly Gave Patient Questionnaire Results on SIGN Trial to Novartis without Consent
February 13, 2014
- SMART Study Sub-Analysis Paper to Be Retracted from JSH Journal
February 12, 2014
- University of Tokyo Besieged with Medical, Pharma Research Woes, School’s Credibility at Stake
February 7, 2014
- JAS Sees “No Need” to Change Its Guidelines in Response to 2013 ACC/AHA Guidelines for the Prevention of ASCVD
February 5, 2014
- SGLT-2 Inhibitors “Suited to Patients with Tendency to Obesity”: Prof. Kadowaki of Univ. of Tokyo
February 4, 2014
- Japan Hypertension Society Won’t Co-Sponsor or Support Drug Maker-Linked Seminars for Now
January 29, 2014
- JCS’s 2013 Guidelines for Treatment of AF Recommend Dabigatran and Apixaban in Moderate-Risk Patients
January 29, 2014
- SMART Study Should Be Removed from CKD Guidelines: Society Panel Chair
January 22, 2014
- SMART Study Retracted from US Journal, Chief Investigator to Resign as Hospital Director
January 22, 2014
- AJMC Announces Guidelines for COI Management at Research and Medical Institutions
December 25, 2013
- Chiba University Finds No Proof of Manipulation in Diovan Study
December 18, 2013
- Nagoya University Denies Diovan Clinical Data Manipulated
December 16, 2013
- Diovan Probe Updates to Come from Nagoya Univ. on Dec. 13, Chiba Univ. on Dec. 17
December 12, 2013
- New Hepatitis C Guidelines Set Triple Therapy Including Simeprevir as 1st Choice
December 11, 2013
- All Clinical Studies Should Follow GCP Requirements: Ex-AZ Chairman Kato
November 26, 2013
- Edoxaban Demonstrates Non-Inferiority to Warfarin in Stroke Prevention in AF Patients: Daiichi Sankyo
November 22, 2013
- AJMC Approves Draft of COI Management Guidelines
November 20, 2013
ページ
Pharma companies have seen Japan’s new “zero” premium coefficient rule extensively applied to medicines with low cost disclosure ratios since its introduction under the drug pricing reform this April. Of new drugs listed in the past two months, all six…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…